AB0425 Real-world effectiveness of Filgotinib in belgian patients with rheumatoid arthritis

De Cock, Diederik;Durez, Patrick;Lenaerts, Jan;Westhovens, René;Verschueren, Patrick
(2023) EULAR 2023 European Congress of Rheumatology — Location: (Italy) Milano (31.May.2023)

Files

2023_EULAR_AB0425.pdf
  • Open Access
  • Adobe PDF
  • 164.79 KB
Download

Details

Authors
  • De Cock, Diederik
    Author
  • Durez, PatrickUCLouvain
    Author
  • Lenaerts, Jan
    Author
  • Westhovens, René
    Author
  • Verschueren, Patrick
    Author
Abstract
BACKGROUND: Filgotinib (FIL), a preferential Janus Kinase (JAK) inhibitor targeting the JAK1 enzyme, has demonstrated efficacy in rheumatoid arthritis (RA) in clinical trials. FIL is reimbursed in Belgium since August 2021 for adult patients with moderate to severe RA with a DAS28 score >3.7 and inadequate response or intolerance to 2 conventional DMARDs including Methotrexate. Today, limited data exist on the real-world effectiveness of FIL in RA. OBJECTIVES: Our aim was to examine the short-term effectiveness of FIL in a heterogeneous RA population. […]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

De Cock, D., Durez, P., Lenaerts, J., Westhovens, R., & Verschueren, P. (2023). AB0425 Real-world effectiveness of Filgotinib in belgian patients with rheumatoid arthritis. Annals of the rheumatic diseases, 82(Suppl 1), 1401. https://doi.org/10.1136/annrheumdis-2023-eular.3694 (Original work published 2023)